drugset / Trial / NCT04285229

A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis

NCT04285229

Phase 3 Completed 147 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).

Timeline

Start
2020-04-10
Primary completion
2021-03-31
Completion
2022-03-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixekizumab Monoclonal antibody 80 mg Subcutaneous

Indications